References
- Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. doi: https://doi.org/10.1038/nrdp.2015.17 PMID: 27188790]
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A. WHO classification of tumours of the central nervous system. Lyon: IARC Press; 2016.
- Vasco C, Canazza A, Rizzo A, Mossa A, Corsini E, Silvani A, Fariselli L, Salmaggi A, Ciusani E. Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. J Neurooncol. 2013;115(3):353–63. doi:https://doi.org/10.1007/s11060-013-1236-x
- Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–50. doi:https://doi.org/10.1111/nan.12432
- Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9. doi:https://doi.org/10.1200/JCO.2007.12.2440
- Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. doi:https://doi.org/10.1056/NEJMoa1308573
- Xu R-H, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65(2):613–21.
- Chiu WT, Shen SC, Chow JM, Lin CW, Shia LT, Chen YC. Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation . Neurobiol Dis. 2010;37(1):118–29. doi:https://doi.org/10.1016/j.nbd.2009.09.015
- Maroon J, Bost J, Amos A, Zuccoli G. Restricted calorie ketogenic diet for the treatment of glioblastoma multiforme. J Child Neurol. 2013;28(8):1002–8. doi:https://doi.org/10.1177/0883073813488670
- Atif F, Yousuf S, Stein DG. Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol. 2015. 2015;146:62–73. doi:https://doi.org/10.1016/j.jsbmb.2014.04.007
- Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond)). 2007;4:5. doi:https://doi.org/10.1186/1743-7075-4-5
- Varshneya K, Carico C, Ortega A, Patil CG. The efficacy of ketogenic diet and associated hypoglycemia as an adjuvant therapy for high-grade gliomas: a review of the literature. Cureus. 2015;7(2):e251doi: https://doi.org/10.7759/cureus.251. eCollection 2015.
- Maroon JC, Seyfried TN, Donohue JP, Bost J. The role of metabolic therapy in treating glioblastoma multiforme. Surg Neurol Int. 2015;6:61. doi:https://doi.org/10.4103/2152-7806.155259
- Clifford J, Barborka CJ. Ketogenic diet treatment of epilepsy in adults. JAMA. 1928;91(2):73–8.
- Nei M, Ngo L, Sirven JI, Sperling MR. Ketogenic diet in adolescents and adults with epilepsy. Seizure. 2014;23(6):439–42. doi:https://doi.org/10.1016/j.seizure.2014.02.015
- Selter JH, Turner Z, Doerrer SC, Kossoff EH. Dietary and medication adjustments to improve seizure control in patients treated with the ketogenic diet. J Child Neurol. 2015;30(1):53–7. doi:https://doi.org/10.1177/0883073814535498
- Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315. doi:https://doi.org/10.1186/1471-2407-11-315
- Meixensberger J, Herting B, Roggendorf W, Reichmann H. Metabolic patterns in malignant gliomas. J Neuro-Oncol. 1995;24(2):153–61.
- Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997;17(3C):1903–11.
- Kiebish MA, Han X, Cheng H, Seyfried TN. In vitro growth environment produces lipidomic and electron transport chain abnormalities in mitochondria from non-tumorigenic astrocytes and brain tumours. ASN Neuro. 2009;1(3):AN20090011.
- Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond)). 2010; Sep 107:74doi:https://doi.org/10.1186/1743-7075-7-74
- Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–52.
- Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L, Shi W. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117(1):125–31. doi:https://doi.org/10.1007/s11060-014-1362-0
- De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, Drewes LR, Geschwind JF, de Graaf RA, Rothman DL. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro-oncology. 2016;18(8):1079–87. doi:https://doi.org/10.1093/neuonc/now088
- Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hídvégi EJ, Hamada H, Sáfrány G. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006;97(6):546–53. doi:https://doi.org/10.1111/j.1349-7006.2006.00208.x
- Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–9. doi:https://doi.org/10.1002/mrm.1910300604
- Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260–4. doi:https://doi.org/10.1002/nbm.698
- Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. JCO. 2009;27(7):1082–6.
- Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, Ben Bashat D. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. J Neurooncol. 2017;132(2):267–75. doi:https://doi.org/10.1007/s11060-016-2364-x
- Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89(7):1375–82. doi:https://doi.org/10.1038/sj.bjc.6601269
- Harrison SD, Jr, Burdeshaw JA, Crosby RG, Cusic AM, Denine EP. Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice. Cancer Res. 1978;38(8):2636–9.
- McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quiñones-Hinojosa A. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery. 2008;63(2):286–9. doi:https://doi.org/10.1227/01.NEU.0000315282.61035.48
- Mayer A, Vaupel P, Struss HG, Giese A, Stockinger M, Schmidberger H. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. Strahlenther Onkol. 2014; Oct190(10):933–8. doi:https://doi.org/10.1007/s00066-014-0696-z
- Tieu MT1, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, Ménard C, Kiehl TR, Perkins BA, Chung C. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol. 2015; Aug124(1):119–26. doi:https://doi.org/10.1007/s11060-015-1815-0
- Noorlag L, De Vos FY2, Kok A, Broekman MLD4, Seute T, Robe PA5, Snijders TJ6. Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies. Clin Nutr. 2019;38(5):1986-1994.
- Klement RJ, Champ CE. Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain. 2017;140(3):e16doi:https://doi.org/10.1093/brain/aww324